An ongoing dialogue on HIV/AIDS, infectious diseases,
Comments are closed.

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- When AI Gets the Medical Advice Wrong — and Right
- ID Things to Be Grateful for — 2025 Edition
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
-
From the Blog — Most Recent Articles
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama December 10, 2025
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
- Favorite ID Fellow Consults: Johns Hopkins Edition November 7, 2025
FROM NEJM — Recent Infectious Disease Articles- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 13, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- High-Dose Influenza Vaccine to Reduce Hospitalizations December 11, 2025In adults 65 to 79 years of age, there appeared to be fewer hospitalizations for influenza or pneumonia with high-dose influenza vaccine than with the standard dose, with a similar incidence of serious adverse events.
- History of Medicine: Smallpox at the Siege of Boston, November 1775–March 1776 December 11, 2025Smallpox played a pivotal role throughout the American Revolution, but the record remains ambiguous about whether British officers weaponized refugees to sow pestilence in the Continental Army.
- Current and Emerging Approaches to Evaluating Influenza Vaccine Performance December 11, 2025Randomized, placebo-controlled trials are widely accepted as the scientific reference standard to determine a causal association between an intervention and an outcome. They are pivotal for product licensure. Although such trials establish safety and efficacy with the assumption that bias has been eliminated, limitations remain. For vaccines, establishing the duration...
- High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults December 11, 2025Among adults 65 years of age or older, a high-dose influenza vaccine did not result in a significantly lower incidence of hospitalization for influenza or pneumonia than a standard-dose vaccine.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 13, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

